The Independent Effect of Level of Kidney Function and Body Composition On Establishing HDL Cholesterol Levels

University of California, Davis0 个研究点目标入组 50 人开始时间: 2008年10月22日最近更新: 2021年2月23日

适应症

干预措施

试验速览

阶段: 不适用
状态: 终止
发起方: University of California, Davis
入组人数: 50
主要终点: LDL Level in Control and Chronic Kidney Disease (CKD3b, CKD4, CKD5) Groups

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

Approximately 20 million people in the United States have some form of kidney failure. People with kidney failure have an increased chance of having low levels of high density lipid (HDL), so called "good cholesterol." Patients who are overweight or obese also have low levels of HDL. The investigators are trying to find out whether causes of low HDL are the same in people who are overweight and in patients with kidney failure so that in the future doctors can better treat low HDL cholesterol levels. People with low levels of HDL are more likely to have heart attacks and strokes and are more likely to lose kidney function. This study hope to learn more about how kidney failure causes low HDL cholesterol levels.

详细描述

This study is not a treatment or outcome trial.This is a single center cross sectional analysis of body composition and lipoprotein level and structure among patients with graded levels of renal failure in comparison to control subjects. To study the relationship between HDL cholesterol and both body composition and insulin resistance measured as homeostatic model assessment (HOMA) among a cohort of non diabetic non-proteinuric patients with advanced chronic kidney disease (CKD) compared to non diabetic subjects having normal kidney function. Renal patients chosen will be with advanced CKD stage 3, Stage 4, and stage 5 - which is end stage renal failure (ESRD) and on hemodialysis. Fasting blood will be taken for the evaluation of baseline lipid and renal function, and blood glucose level to make sure that there is no recent evidence of diabetes. Body compositions will be measured with 2 established methods: DEXA and whole body bio-impedance spectroscopy (BIS). Fat mass and analysis will be estimated so as to provide a relationship between adiposity, insulin resistance, residual renal function and HDL levels and structure.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Cross Sectional

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•self report of stable body weight during the past six months;
•BMI 18-40 kg/m2; Hemodialysis dependent for at least 3 months, prevalent ESRD (end stage renal disease) cohort;
•GFR > 15 < 44 ml/min (CKD cohort);
•GFR > 60 ml/min (Control cohort).

排除标准

•Diabetes Mellitus (American Diabetes Association definition: fasting glucose >120 mg/dl);
•Evidence of liver disorder, ie; hepatitis
•Evidence of thyroid disorders
•HIV by medical history (HIV test will not be performed)
•Renal transplant recipient
•Oral contraceptive/ hormone replacement therapy
•Systemic use of systemic or inhaled corticosteroids in the past month
•Contraindication to systemic anticoagulation (heparin administration is necessary to measure levels of LPL, HL);
•Hemoglobin < 8.5 g/dl (anemia);
•Current, within 2 months use of any hypolipidemic or anti-diabetic agents;
•Patients treated with a fibric acid derivative or niacin in the past 4 weeks;
•Urinary protein excretion of greater than 0.5 grams per day;
•Any other condition that, in the opinion of the investigators, would put the subject at risk.

研究组 & 干预措施

control

heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60

干预措施: Heparin (Drug)

chronic renal disease (CKD3b)

heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45

干预措施: Heparin (Drug)

chronic renal disease (CKD4)

heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30

干预措施: Heparin (Drug)

chronic renal disease (CKD5)

heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis

干预措施: Heparin (Drug)